Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection

Arthritis Care and Research

Volumn 67, Issue 4, 2015, Pages 467-474

  Patel, Ruchika ^a   Mikuls, Ted R ^b   Richards, John S ^c   Kerr, Gail ^c   Cannon, Grant W ^c   Baker, Joshua F ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; HYDROXYCHLOROQUINE; METHOTREXATE; PREDNISONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; ANTIVIRUS AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AFRICAN AMERICAN; AGED; ARTHRALGIA; ARTICLE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CLINICAL FEATURE; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISABILITY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DRUG USE; FEMALE; GENERALIZED ESTIMATING EQUATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; JOINT SWELLING; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MIDDLE AGED; MULTICENTER STUDY; PAIN; PATIENT GLOBAL ASSESSMENT; PHYSICIAN GLOBAL ASSESSMENT; PROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK; SMOKING; VETERAN; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; REGISTER; TREATMENT OUTCOME;

AGED; ANTIRHEUMATIC AGENTS; ANTIVIRAL AGENTS; ARTHRITIS, RHEUMATOID; COMORBIDITY; FEMALE; HEPATITIS C; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PREDNISONE; PROSPECTIVE STUDIES; REGISTRIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VETERANS;

EID: 84925423384     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22463     Document Type: Article

References (34)

1. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE,. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum 2010; 62: 1576-82.
2. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341: 556-62.
3. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep 2012; 61: 1-32.
4. Parke FA, Reveille JD,. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004; 51: 800-4.
5. Backus LI, Belperio PS, Loomis TP, Yip GH, Mole LA,. Hepatitis C virus screening and prevalence among US veterans in Department of Veterans Affairs care. JAMA Intern Med 2013; 173: 1549-52.
6. Mikuls TR, Fay BT, Michaud K, Sayles H, Thiele GM, Caplan L, et al. Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford) 2011; 50: 101-9.
7. Iannone F, La Montagna G, Bagnato G, Gremese E, Giardina A, Lapadula G,. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial. J Rheumatol 2014; 41: 286-92.
8. Cansu DU, Kalifoglu T, Korkmaz C,. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008; 35: 421-4.
9. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, et al. Safety of anti-tumor necrosis factor-α therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35: 1944-9.
10. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-24.
11. Tyson GL, Kramer JR, Duan Z, Davila JA, Richardson PA, El-Serag HB,. Prevalence and predictors of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients. Hepatology 2013; 58: 538-45.
12. Sales MM, Cunningham FE, Glassman PA, Valentino MA, Good CB,. Pharmacy benefits management in the Veterans Health Administration: 1995 to 2003. Am J Manag Care 2005; 11: 104-12.
13. Cannon GW, Mikuls TR, Hayden CL, Ying J, Curtis JR, Reimold AM, et al. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice. Arthritis Care Res (Hoboken) 2011; 63: 1680-90.
14. Ramos-Casals M, Jara LJ, Medina F, Rosas J, Calvo-Alen J, Mana J, et al. Systemic autoimmune diseases co-existing with chronic hepatitis C virus infection (the HISPAMEC Registry): patterns of clinical and immunological expression in 180 cases. J Intern Med 2005; 257: 549-57.
15. Studenic P, Radner H, Smolen JS, Aletaha D,. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. Arthritis Rheum 2012; 64: 2814-23.
16. Baker JF, Conaghan PG, Smolen JS, Aletaha D, Shults J, Emery P, et al. Development and validation of modified disease activity scores in rheumatoid arthritis: superior correlation with magnetic resonance imaging-detected synovitis and radiographic progression. Arthritis Rheumatol 2014; 66: 794-802.
17. Buskila D, Shnaider A, Neumann L, Lorber M, Zilberman D, Hilzenrat N, et al. Musculoskeletal manifestations and autoantibody profile in 90 hepatitis C virus infected Israeli patients. Semin Arthritis Rheum 1998; 28: 107-13.
18. Lee YH, Ji JD, Yeon JE, Byun KS, Lee CH, Song GG,. Cryoglobulinaemia and rheumatic manifestations in patients with hepatitis C virus infection. Ann Rheum Dis 1998; 57: 728-31.
19. Cacoub P, Poynard T, Ghillani P, Charlotte F, Olivi M, Piette JC, et al, for the MULTIVIRC Group. Extrahepatic manifestations of chronic hepatitis C. Arthritis Rheum 1999; 42: 2204-12.
20. Barkhuizen A, Rosen HR, Wolf S, Flora K, Benner K, Bennett RM,. Musculoskeletal pain and fatigue are associated with chronic hepatitis C: a report of 239 hepatology clinic patients. Am J Gastroenterol 1999; 94: 1355-60.
21. Buskila D,. Hepatitis C-associated arthritis. Curr Opin Rheumatol 2000; 12: 295-9.
22. Lormeau C, Falgarone G, Roulot D, Boissier MC,. Rheumatologic manifestations of chronic hepatitis C infection. Joint Bone Spine 2006; 73: 633-8.
23. El-Serag HB, Kunik M, Richardson P, Rabeneck L,. Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123: 476-82.
24. Mikuls TR, Padala PR, Sayles HR, Yu F, Michaud K, Caplan L, et al. Prospective study of posttraumatic stress disorder and disease activity outcomes in US veterans with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2013; 65: 227-34.
25. Wasley A, Grytdal S, Gallagher K, Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis: United States, 2006. MMWR Surveill Summ 2008; 57: 1-24.
26. Rosenblum A, Marsch LA, Joseph H, Portenoy RK,. Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol 2008; 16: 405-16.
27. Bezemer G, van Gool AR, Verheij-Hart E, Hansen BE, Lurie Y, Esteban JI, et al. Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life: an international, multicenter, randomized, controlled study. BMC Gastroenterol 2012; 12: 11.
28. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F,. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology 2005; 41: 790-800.
29. Armah KA, Quinn EK, Cheng DM, Tracy RP, Baker JV, Samet JH, et al. Human immunodeficiency virus, hepatitis C, and inflammatory biomarkers in individuals with alcohol problems: a cross-sectional study. BMC Infect Dis 2013; 13: 399.
30. Che W, Zhang B, Liu W, Wei Y, Xu Y, Hu D,. Association between high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with hepatitis C virus infection. Mediators Inflamm 2012; 2012: 730923.
31. Atta M, Cabral M, Santos G, Parana R, Atta A,. Inflammation biomarkers in chronic hepatitis C: association with liver histopathology, HCV genotype and cryoglobulinemia. Inflamm Res 2012; 61: 1101-6.
32. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
33. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.
34. Udina M, Castellvi P, Moreno-Espana J, Navines R, Valdes M, Forns X, et al. Interferon-induced depression in chronic hepatitis C: a systematic review and meta-analysis. J Clin Psychiatry 2012; 73: 1128-38.